Prophylaxis in hereditary angioedema: a United Kingdom Delphi Consensus

Following changes to available treatments since the last consensus statement in 2014, a further Delphi consensus was conducted in 2021 to establish consensus on the use of long-term prophylaxis for the management of HAE in the UK, and highlight areas where there could be improvement.¹

This promotional material was initiated, funded and developed by Takeda. It is intended for UK Healthcare Professionals only.

TAKHZYRO is indicated for routine prevention of recurrent attacks of HAE in patients aged 2 years and older.4,5

CINRYZE is indicated for the treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2-years old and above) with HAE; routine prevention of angioedema attacks in adults, adolescents and children (6-years old and above) with severe and recurrent attacks of HAE, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.6,7

This project was facilitated by an independent health care consultancy, the MASS Team, initiated and funded by Takeda UK. This summary is written and funded by Takeda, but Takeda had no involvement in the interpretation or the writing of the full publication.
*No attack metric connected to access of TAKHZYRO in Germany, France and Spain.

Abbreviations: CCP, clinical commissioning policy; HAE, hereditary angioedema; HCP, healthcare professional; LTP, long-term prophylaxis; NICE, National Institute for Health and Care Excellence; PRO, patient-reported outcome; QoL, quality of life; WAO/EAACI, World Allergy Organization/European Academy of Allergy and Clinical Immunology.

References: 1. Yong PFK, et al. Clin Exp Immunol 2024;217(1);100–116; 2. Maurer M, et al. Allergy. 2022;77(7):1961–1990; 3. Sundler Björkman L, et al. Clin Transl Allergy. 2022;12(3):e12135; 4. TAKHZYRO GB Summary of Product Characteristics; 5. TAKHZYRO NI Summary of Product Characteristics; 6. CINRYZE GB Summary of Product Characteristics; 7. CINRYZE NI Summary of Product Characteristics.